Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ligelizumab in food allergy
NL-OMON60484Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ligelizumab in food allergy, sponsored by Novartis. Primary endpoint: Overall incidence and exposure-adjusted occurrence rates of treatment-emergent adverse events and serious adverse events. Started Oct 2023; status: completed.
02
Drugs
ligelizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on NL-OMON60484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60484.